Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
52.45
-0.71 (-1.34%)
Feb 21, 2025, 4:00 PM EST - Market closed
Mirum Pharmaceuticals Revenue
Mirum Pharmaceuticals had revenue of $90.38M in the quarter ending September 30, 2024, with 89.37% growth. This brings the company's revenue in the last twelve months to $307.03M, up 112.14% year-over-year. In the year 2023, Mirum Pharmaceuticals had annual revenue of $186.37M with 141.85% growth.
Revenue (ttm)
$307.03M
Revenue Growth
+112.14%
P/S Ratio
8.05
Revenue / Employee
$1,162,985
Employees
264
Market Cap
2.52B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
MIRM News
- 1 day ago - US FDA approves Mirum Pharma's genetic disorder drug - Reuters
- 3 days ago - Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025 - Business Wire
- 11 days ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates - Business Wire
- 6 weeks ago - Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3) - Seeking Alpha
- 6 weeks ago - Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Mirum Pharma: Buy At Dips For Volixibat Potential - Seeking Alpha
- 3 months ago - Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting - Business Wire